Avalo Therapeutics Q3 EPS $(0.11) Down From $0.34 YoY, Sales $236.00K Down From $14.95M YoY
Portfolio Pulse from Benzinga Newsdesk
Avalo Therapeutics reported Q3 losses of $(0.11) per share, a 132.35% decrease YoY. The company's sales also decreased by 98.42% to $236.00K from $14.95M in the same period last year.
November 09, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Avalo Therapeutics reported a significant decrease in earnings and sales YoY, which could negatively impact the company's stock price.
Avalo Therapeutics reported a significant decrease in earnings and sales compared to the same period last year. This indicates a poor financial performance, which could lead to a decrease in investor confidence and a potential drop in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100